C-type natriuretic peptide (CNP) is a potent, endothelial-derived relaxant and growth-inhibitory factor. Accelerated vascular disease is an important cause of morbidity in cardiac transplant recipients, and endothelial dysfunction is now well recognized in patients with cardiovascular disease. CNP has not previously been investigated following cardiac transplantation. We therefore studied plasma levels of immunoreactive CNP in patients early and late after heart transplantation, compared with levels in healthy subjects. We measured CNP in extracted human plasma using an antibody against human CNP-(1–22). CNP levels were significantly elevated in 13 cardiac recipients 2 weeks post-transplant [2.64±0.26 pmol/l (mean±S.E.M.)] compared with those in the normal healthy subjects (0.62±0.04 pmol/l; n = 20, P < 0.001). Plasma levels of CNP were also significantly elevated in a second group of established cardiac transplant recipients (1.15±0.07 pmol/l; n = 46) studied 1–13 years post-transplant when compared with the healthy subjects (P < 0.001). In the group studied later after transplantation, CNP levels were significantly associated with systolic blood pressure (P < 0.05) and were higher in patients with angiographic post-transplant coronary artery disease (P = 0.032). In conclusion, these findings clearly demonstrate that CNP is elevated soon after cardiac transplantation and remains raised in patients even several years post-transplant. CNP may be important as a circulating or local hormone involved in vascular contractile function and in the pathophysiology of cardiac allograft vasculopathy following heart transplantation.
Skip Nav Destination
Close
Article navigation
November 2000
Research Article|
October 26 2000
Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy
Martin G. BUCKLEY;
Martin G. BUCKLEY
*Imperial College at the National Heart & Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, U.K.
Search for other works by this author on:
Geraint H. JENKINS;
Geraint H. JENKINS
*Imperial College at the National Heart & Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, U.K.
Search for other works by this author on:
Andrew G. MITCHELL;
Andrew G. MITCHELL
*Imperial College at the National Heart & Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, U.K.
Search for other works by this author on:
Magdi H. YACOUB;
Magdi H. YACOUB
*Imperial College at the National Heart & Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, U.K.
Search for other works by this author on:
Donald R. J. SINGER
†Department of Pharmacology & Clinical Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, U.K.
Correspondence: Dr Donald R. J. Singer (e-mail d.singer@sghms.ac.uk) and Dr Martin G. Buckley, Imperial College at the National Heart & Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, U.K.
Search for other works by this author on:
Clin Sci (Lond) (2000) 99 (5): 467–472.
Article history
Received:
January 04 2000
Revision Received:
April 19 2000
Accepted:
May 30 2000
Citation
Martin G. BUCKLEY, Geraint H. JENKINS, Andrew G. MITCHELL, Magdi H. YACOUB, Donald R. J. SINGER; Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond) 1 November 2000; 99 (5): 467–472. doi: https://doi.org/10.1042/cs0990467
Download citation file:
Close
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
2
Views
0
Citations
Cited By
Related Articles
A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy
Clin Sci (Lond) (June,2016)
A novel transcriptional factor with Ser/Thr kinase activity involved in the transforming growth factor (TGF)-β signalling pathway
Biochem J (August,2000)